-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
Recently, the CDE official website showed that Hengrui cyclophosphamide capsules are planned to be included in the priority review and are suitable for the treatment of lymphoma, leukemia, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, breast cancer and many other tumor types
At the same time, the default license of the CDE clinical trial shows that the clinical application of two new drugs of Shengdia has been approved by the National Food and Drug Administration.
Cyclophosphamide capsule is a DNA alkylating agent and cytotoxic immunosuppressant.
Cyclophosphamide was developed by BAXTER and was approved by the FDA in 1959 (cyclophosphamide tablets and cyclophosphamide injections), and has now been withdrawn from the market